No Data
No Data
Lisata to Use Haystack Technology to Evaluate Pancreatic Cancer Asset Certepetide
Express News | Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack Mrd™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
Express News | EXCLUSIVE: Lisata Therapeutics Tells Benzinga Co. And Haystack Oncology Initiate Research Collaboration To Use The Haystack MRD Technology To Evaluate Efficacy Of Pancreatic Cancer Therapy
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
Lisata Therapeutics, Inc.’s (LSTA Quick QuoteLSTA - Free Report) lead pipeline candidate is certepetide (formerly known as LSTA1), which is being developed for treating a range of solid tumors.
Express News | Lisata Therapeutics Inc: Complete Enrollment Achieved Nearly Six Months Ahead of Plan
Express News | Lisata Therapeutics Inc - Addition of Second-Line Cholangiocarcinoma Arm to Bolster Trial
No Data